Regional therapy of hepatic metastases

Hematology/Oncology Clinics of North America

Volumn 16, Issue 4, 2002, Pages 947-967

  Fraker, Douglas L ^a   Soulen, Michael ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTINEOPLASTIC AGENT; CETUXIMAB; CISPLATIN; COLLAGEN; DEXAMETHASONE; DOXORUBICIN; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IODINATED POPPYSEED OIL; IRINOTECAN; ISOTOPE; LIQUID NITROGEN; MITOMYCIN C; OXALIPLATIN; POLYVINYL ALCOHOL; TYROSINE KINASE RECEPTOR;

ARTERY THROMBOSIS; ARTIFICIAL EMBOLISM; BILE DUCT DISEASE; CANCER CONTROL; CANCER SURVIVAL; CHOLECYSTITIS; CLINICAL TRIAL; CRYOSURGERY; DIARRHEA; DRUG INDUCED DISEASE; ELECTRODE; GENE THERAPY; HEAT; HEPATITIS; HUMAN; INFUSION PUMP; JAUNDICE; LIVER ABSCESS; LIVER FAILURE; LIVER METASTASIS; LIVER RESECTION; LIVER TOXICITY; NEUTROPENIA; ONCOLOGY; PRIORITY JOURNAL; RADIOFREQUENCY RADIATION; REVIEW; SURGICAL APPROACH; SURVIVAL TIME; TREATMENT INDICATION;

ANTINEOPLASTIC AGENTS; CATHETER ABLATION; COLORECTAL NEOPLASMS; CRYOSURGERY; EMBOLIZATION, THERAPEUTIC; FLUOROURACIL; HEPATIC ARTERY; HUMANS; LIVER NEOPLASMS; SURGICAL PROCEDURES, OPERATIVE;

EID: 0036701056     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(02)00039-4     Document Type: Review

References (55)

1. Fraker DL. Regional therapies of cancer. In: Norton JA, Bolinger L, Change KE, et al, editors. Surgery: Scientific Basis and Current Practice. New York: Springer-Verlag; 2001. p. 1863-80.
2. Talbot SM, Neugut AI. Epidemiological trends in colorectal cancer. In: Saltz L, editor. Colorectal Cancer: Multimodality Management. Totowa, NJ: Humana Press.
3. Collins JM. Pharmacologic rationale for hepatic arterial therapy. Recent Results Cancer Res 1986;100:140-7.
4. Sigurdson ER, Ridge JA, Kemeny N, Daly JM. Tumor and liver drug uptake following hepatic artery and portal vein infusion in man. J Clin Oncol 1987;5:1836-40.
5. Van der Eb MM, Hoeben RC, van de Velde CJ. Towards gene therapy for colorectal liver metastases. Recent Results Cancer Res 1998;147:173-86.
6. Grem JL. 5-Fluorouracil and its biomodulation in the management of colorectal cancer. In: Saltz L, editor. Colorectal Cancer: Multimodality Management. Totowa, NJ: Humana Press.
7. Saltz LB. The role of irinotecan in colorectal cancer. Curr Oncol Rep 1999;1:155-60.
8. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-14.
9. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomized trial. Lancet 2000;355:1041-7.
10. Rowinsky EK. Selected targets and rationally designed therapeutics for patients with colorectal cancer. In: Saltz L, editor. Colorectal cancer: multimodality management. Totowa, NJ: Humana Press.
11. Curley SA, Izzo F, Delrio P, et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: Results in 123 patients. Ann Surg 1999;230:1-8.
12. Ron JG, Kemeny NE, Gon B, et al. Phase I/II study of escalating doses of systemic irinotecan (CPT-11) with hepatic arterial infusion of floxuridine (FUDR) and dexamethasone (D), with or without cryosurgery for patients with unresectable hepatic metastases from colorectal cancer. Proc ASCO 1999;18:908.
13. Neiderhuber JE, Ensminger W, Gyves J, Thrall J, Walker S, Cozzi E. Regional chemotherapy of colorectal cancer metastatic to the liver. Cancer 1984;53:1336-43.
14. Hohn DC, Stagg RJ, Friedman MA, et al. A randomized trial of continuous intravenous versus hepatic intra-arterial floxuridine in patients with colorectal cancer metastatic to the liver: The Northern California Oncology Group Trial. J Clin Oncol 1989;7:1646-54.
15. Chang A, Schneider PD, Sugarbaker PH, et al. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal metastases. Ann Surg 1987;206:685-93.
16. Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P. Intrahepatic or systemic infusion of fluorodeoxyruidine in patients with liver metastases from colorectal carcinoma. Ann Intern Med 1987;107:459-65.
17. Martin J, O'Connelll M, Wieand H, et al. Intra-arterial floxuridine versus systemic fluorouracil for hepatic metastases from colorectal cancer: A randomized trial. Arch Surg 1990;125:1022-27.
18. Rougler PH, Laplanche A, Huguier M, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: Long-term results of a prospective randomized trial. J Clin Oncol 1992;10:1112-18.
19. Allen-Mersh TG, Earlam S, Fordy C. Quality of life and survival with continuous hepatic artery infusion for colorectal liver metastases. Lancet 1994;344:1255-60.
20. Patt YZ. Regional hepatic arterial chemotherapy for colorectal cancer metastatic to the liver: The controversy continues. J Clin Oncol 1993;11:815-19.
21. Kemeny N, Conti J, Cohen A, et al. A phase 2 study of hepatic arterial FUDR, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol 1994;12:2288-95.
22. Stagg R, Venook A, Chase J, et al. Alternating hepatic intraarterial floxuridine and fluorouracil: A less toxic regimen for treatments of liver metastases from colorectal cancer. J Natl Cancer Inst 1991;83:423-28.
23. Kemeny N, Gonen M, Sillivan D, et al. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol 2001;19:2687-95.
24. Venook AP, Warren RS. Regional chemotherapy approaches for primary and metastatic liver tumors. Surg Oncol Clin North Am 1996;5:411-27.
25. Fong Y, Fortner JG, Sun R, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 1999;230:309-21.
26. Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: Surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy. An intergroup study. J Clin Oncol 2002;20:1499-505.
27. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapoy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999;34:2039-48.
28. Konno T. Targeting cancer chemotherapeutic agents by use of Lipiodol contrast medium. Cancer 1999;66:1897-903.
29. Egawa H, Maki A, Mori K. Effects of intraarterial chemotherapy with a new lipophilic anticancer agent, estradiol-chlorambucil (KMM2210), dissolved in Lipiodol on experimental liver tumors in rats. J Surg Oncol 1990;44:109-14.
30. Nakamura H, Hashimoto T, Oi H, et al. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989;170:783-68.
31. Sasaki Y, Imaoka S, Kasugai H, et al. A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer 1987;60:1194-203.
32. Kruskal JB, Hlaty L, Hahnfeldt P, et al. In-vivo and in-vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors. J Vasc Interv Radiol 1993;4:741-48.
33. Daniels JR, Sternlicht M, Daniels AM. Collagen chemoembolization: Pharmacokinetics and tissue tolerance of cisplatin in liver and kidney. Cancer Res 1988;48:2446.
34. Pentecost MJ, Daniels JR, Teitelbaum GP, et al. Hepatic chemoembolization: Safety with portal vein thrombosis. J Vasc Interv Radiol 1993;4:347-51.
35. Leung DA, Goin JE, Sickles C, Soulen MC. Determinants of post-embolization syndrome following hepatic chemoembolization. J Vasc Interv Radiol 2001;12:321-6.
36. Kim W, Clark TWI, Baum RA, Soulen MC. Risk factors for liver abscess formation following hepatic chemoembolization. J Vasc Interv Radiol 2001;12:965-8.
37. Lang EK, Brown CL Jr. Colorectal metastases to liver: Selective chemoembolization. Radiology 1993;189:417-22.
38. Sanz-Altamira PM, Spence LD, Huberman MS, et al. Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma. Dis Colon Rectum 1997;40:770-5.
39. Tellez C, Benson III AB, Lyster MY, et al. Phase 2 trial ofchemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer 1998;82:1250-59.
40. Tuite CM, Soulen MC, Baum RA, et al. Hepatic metastases from colorectal cancer treated with CAM/Ethiodol/PVA chemoembolization: Evaluation of survival, biologic and morphologic response. J Vasc Interv Radiol 1999;10:260.
41. Fraker DL, Alexander HR. Isolated limb perfusion of the liver. In: Lotze MT, Rubin JT, editors. Regional Therapy of Advanced Cancer. Philadelphia: Lippincott-Raven; 1997. p. 141-50.
42. Ravikumar TS, Pizzomo G, Bodden W, et al. Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors. J Clin Oncol 1994;12:2723-36.
43. Oldhafer KJ, Lang H, Frerker M, et al. First experience and technical aspects of isolated liver perfusion for extensive liver metastases. Surgery 1998;126:622-31.
44. Alexander HR, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 1998;16:1479-89.
45. Alexander HR, Libutti SK, Bartlett DL, Puhlmann M, Fraker DL, Bachenheimer LC. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to the liver. Clin Cancer Res 2000;6:3062-70.
46. Weaver ML, Atkinson D, Zemel R. Hepatic cryosurgery in treating colorectal metastases. Cancer 1995;76:210-4.
47. Sarantou T, Bilchik A, Ramming KP. Complications of hepatic cryosurgery. Semin Surg Oncol 1998;14:156-62.
48. McGahan JP, Dodd GD. Radiofrequency ablation of the liver: Current status. AJR Am J Roentgenol 2001;176:3-16.
49. Fraker DL. Radiofrequency ablation of colorectal metastases to the liver. In: Saltz L, editor. Colorectal Cancer: Multimodality Management. Totowa, NJ: Humana Press.
50. Siperstein A, Garland A, Engle K, et al. Laparoscopic radiofrequency ablation of primary and metastatic liver tumors. Surg Endosc 2000;14:400-5.
51. Curley SA, Izzo F, Eeirio P, et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies. Ann Surg 1999;230:1-8.
52. Siperstein A, Garland A, Engle K, et al. Local recurrence after laparoscopic radiofrequency thermal ablation of hepatic tumors. Ann Surg Oncol 2000;7:106-13.
53. Wood TF, Rose DM, Chung M, Allegra DP, Foshag LI, Bilchik AJ. Radiofrequency ablation of 231 unresectable hepatic tumors: Indications, limitations, and complications. Ann Surg Oncol 2000;7:593-600.
54. deBaere T, Elias D, Dromain C, et al. Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol 2000;175:1619-25.
55. Kesmodel SB, Canter RJ, Raz DJ, Bauer TW, Spitz FR, Fraker DL. Survival following regional treatment for metastatic colorectal cancer to the liver using radiofrequency ablation and hepatic artery infusion pump placement. Ann Surg Oncol 2002;9:S68.